A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Clinical trial NCT05033691 · RECRUITING

Trial details

NCT number: NCT05033691
Sponsor: Hadassah Medical Organization
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

NSCLC EGFR Gene Mutation EGF-R Positive Non-Small Cell Lung Cancer Non-small Cell Lung Cancer Brain Metastases

Start date: 2021-03-09
Primary completion: 2024-12-31
Enrollment: 162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.